SABA Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: March 27, 2026
Report Source: 2025 Annual Report
Saba Capital Income & Opportunities Fund II. Stock Analysis SABA
Saba Capital Income & Opportunities Fund II is a US-based company operating in industry. The company is headquartered in Fort Lauderdale, Florida. Saba Capital Income & Opportunities Fund II (the Fund), formerly Templeton Global Income Fund, is a closed-end management investment company. The Fund seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. The Fund invests globally in debt and equity securities of public and private companies, which includes, among other things, investments in closed-end funds, special purpose acquisition companies (SPACs), reinsurance, and public and private debt instruments. The Fund also may utilize derivatives, including total return swaps, credit default swaps, options and futures, in seeking to enhance returns and/or to reduce portfolio risk. The Fund may also invest up to 15% of its total assets in private funds on a discretionary basis. The Fund’s manager is Saba Capital Management, LP.
Read More Saba Capital Income & Opportunities Fund II (SABA) Chart
Key Statistics of Saba Capital Income & Opportunities Fund II (SABA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$8.44Volume
21.74KP/E Ratio (TTM)
-52 Week Range
Market Cap
231.43MAvg. Volume
55.67KDividend Yield
-Financial Metrics & Statements of Saba Capital Income & Opportunities Fund II (SABA)
FAQ's for Saba Capital Income & Opportunities Fund II (SABA)
- According to Musaffa’s Shariah screening methodology, Saba Capital Income & Opportunities Fund II (SABA) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.